无创多期CT人工智能预测结直肠癌治疗前肿大淋巴结状态的前瞻性验证研究
本研究回顾性开发并前瞻性验证基于多期CT影像组学的机器学习分类器,用于评估结直肠癌治疗前肿大肿瘤引流淋巴结(长径≥10 mm)的状态。融合多区域病变特征及临床变量的Clinical_LnNAV模型表现最佳,AUC为0.839,准确率76.6%,敏感度67.7%,特异度89.1%。该工具可能辅助临床制定个体化治疗方案。
要点
- 治疗前多期CT影像组学联合临床变量评估肿大肿瘤引流淋巴结,特异度达89.1%。
- 肿大淋巴结融合多期CT分类器LnNAV的AUC为0.820,AUPRC为0.883。
- 模型可能辅助避免不适当的术前辅助治疗和不必要的扩大淋巴结清扫。
核心结论
- 基于多期CT影像组学联合临床变量的Clinical_LnNAV分类器在评估结直肠癌治疗前肿大肿瘤引流淋巴结状态方面表现出良好性能,可能辅助临床制定个体化治疗方案。
研究设计与样本
- 研究纳入430例经病理确诊并接受根治性切除的结直肠癌患者,开发队列319例(2015年1月至2019年12月,回顾性入组),测试队列111例(2020年1月至2023年5月,前瞻性入组)。从多期CT多区域病变(肿瘤和肿大肿瘤引流淋巴结)提取影像组学特征,经严格特征选择后训练多个机器学习分类器,以受试者工作特征曲线下面积(AUROC)最优者进行验证。
诊断标准与关键数值
- 共构建15个基于多区域病变特征的分类器(TumorN、A、V;LnN、A、V;Ln为淋巴结,N为非增强期,A为动脉期,V为静脉期)。肿大肿瘤引流淋巴结融合多期CT分类器LnNAV的AUROC为0.820,AUPRC为0.883。整合治疗前临床变量后(Clinical_LnNAV),AUROC为0.839,AUPRC为0.903,准确率76.6%,敏感度67.7%,特异度89.1%。
临床应用与阅片要点
- 作者认为该分类器可能辅助临床医生为结直肠癌患者制定个体化治疗方案,可能有助于避免不适当的术前辅助治疗和不必要的扩大淋巴结清扫。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Benign lymph node enlargement can mislead surgeons into overstaging colorectal cancer (CRC), causing unnecessarily extended lymphadenectomy. This study aimed to develop and validate a machine learning (ML) classifier utilizing multi-phase CT (MPCT) radiomics for accurate evaluation of the pre-treatment status of enlarged tumor-draining lymph nodes (TDLNs; defined as long-axis diameter ≥ 10 mm).
MATERIALS AND METHODS: This study included 430 pathologically confirmed CRC patients who underwent radical resection, stratified into a development cohort (n = 319; January 2015-December 2019, retrospectively enrolled) and test cohort (n = 111; January 2020-May 2023, prospectively enrolled). Radiomics features were extracted from multi-regional lesions (tumor and enlarged TDLNs) on MPCT. Following rigorous feature selection, optimal features were employed to train multiple ML classifiers. The top-performing classifier based on area under receiver operating characteristic curves (AUROCs) was validated.
RESULTS: Ultimately, 15 classifiers based on features from multi-regional lesions were constructed (TumorN, A, V; LnN, A, V; Ln, lymph node; N, non-contrast phase; A, arterial phase; V, venous phase). Among all classifiers, the enlarged TDLNs fusion MPCT classifier (LnNAV) demonstrated the highest predictive efficacy, with AUROCs and AUPRCs of 0.820 and 0.883, respectively. When pre-treatment clinical variables were integrated (Clinical_LnNAV), the model's efficacy improved, with AUROCs of 0.839, AUPRCs of 0.903, accuracy of 76.6%, sensitivity of 67.7%, and specificity of 89.1%.
CONCLUSION: The classifier Clinical_LnNAV demonstrated well performance in evaluating pre-treatment status of enlarged TDLNs. This tool may support clinicians in developing individualized treatment plans for CRC patients, helping to avoid inappropriate treatment.
KEY POINTS: Question There are currently no effective non-invasive tools to assess the status of enlarged tumor-draining lymph nodes in colorectal cancer prior to treatment. Findings Pre-treatment multi-phase CT radiomics, combined with clinical variables, effectively assessed the status of enlarged tumor-draining lymph nodes, achieving a specificity of 89.1%. Clinical relevance statement The multi-phase CT-based classifier may assist clinicians in developing individualized treatment plans for colorectal cancer patients, potentially helping to avoid inappropriate preoperative adjuvant therapy and unnecessary extended lymphadenectomy.
引用
- Sun K, Wang J, Wang B, et al. Non-invasive multi-phase CT artificial intelligence for predicting pre-treatment enlarged lymph node status in colorectal cancer: a prospective validation study. Eur Radiol. 2025. PMID: 40506635. doi:10.1007/s00330-025-11723-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。